SC-0245

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameSC-0245
Drug Alias NameSC0245SC-0245
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsSolid tumoursSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShijiazhuang Zhikang Hongren New Drug Development Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi BioCity
Inactive CompaniesShijiazhuang Zhikang Hongren New Drug Development Co Ltd
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A